

- | | | |
|--------------------|-------------------|-----------------------------|
| Altwein, J.E. 62 | Jakse, G. 22 | Oberpenning, F. 57 |
| Augustin, H. 80 | Jung, P. 22 | Otto, T. 32 |
| Baumgartner, R. 27 | Knuechel, R. 27 | Pummer, K. 57, 80 |
| Brauers, A. 22 | Krege, S. 32 | Rübben, H. 32 |
| Fichtner, J. 40 | Kriegmair, M. 27 | Schmid, H.-P. 5, 10, 57, 80 |
| Fischer, C.G. 10 | Luboldt, H.J. 62 | Trummer, H. 80 |
| Hakenberg, O.W. 72 | Mickisch, G.H. 16 | Weißbach, L. 46 |
| Hofstetter, A. 27 | Miller, K. 5, 6 | Wirth, M.P. 5, 72 |
| Hubmer, G. 80 | Noll, F. 32 | Zaak, D. 27 |

Subject Index Vol. 63, 1999

- | | | |
|---------------------------------|--------------------------------------|--|
| 5-Aminolevulinic acid 27 | Intermittent androgen suppression 80 | Protoporphyrin IX 27 |
| Adjuvant treatment 72 | Maximal androgen blockade 80 | Radical prostatectomy 72 |
| Algorithm 22 | Metastasis 10 | Recurrence 32 |
| Bladder cancer 22, 27 | Metastatic renal cancer 16 | Renal cell carcinoma 6 |
| Bladder carcinoma 32 | New concepts of hormonal therapy 80 | Staging 57 |
| Bone scintigraphy 57 | Overview 16 | Surgical procedures 10 |
| Carcinoma, renal cell 10 | Pelvic lymphadenectomy 57 | Surgical therapy 16 |
| Complications 40 | Photosensitizer 27 | T ₁ G ₃ bladder carcinoma 32 |
| Diagnosis 22, 46, 57 | Preneoplasia 27 | Testicular cancer 46 |
| Diagnostic standards 6 | Prognostic factors 62 | Therapeutic standards 6 |
| Digital rectal examination 57 | Progression 32 | Therapy 46 |
| Evidence-based medicine 72 | Prostate cancer 72 | Transrectal ultrasonography 57 |
| Follow-up 40 | Prostate-specific antigen 57 | Tumor nephrectomy 6 |
| Immunotherapy 6, 16 | Prostatic carcinoma 57, 62 | Urinary diversion 40 |
| Interdisciplinary guidelines 46 | | |